Summit Therapeutics
SMMT
10 hedge funds and large institutions have $18.3M invested in Summit Therapeutics in 2016 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 0 closing their positions.
9% less funds holding
Funds holding: 11 → 10 (-1)
44% less capital invested
Capital invested by funds: $32.6M → $18.3M (-$14.3M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.15K |
Top Sellers
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$363K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$27.2K |
| 3 |
Morgan Stanley
New York
|
-$8 |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Point72 Asset Management
Stamford,
Connecticut
| $6.34M | -$8 | -1 | -0% |
|
|
LPU
2
Lansdowne Partners (UK)
London,
United Kingdom
| $6.34M | – | – | – |
|
3
Axa
Paris,
France
| $2.57M | – | – | – |
|
|
SFM
4
Sphera Funds Management
Tel Aviv,
Israel
| $1.39M | -$27.2K | -3,357 | -2% |
|
5
First Eagle Investment Management
New York
| $1.23M | – | – | – |
|
|
EAM
6
EverPoint Asset Management
Stamford,
Connecticut
| $376K | -$363K | -44,889 | -45% |
|
7
Wells Fargo
San Francisco,
California
| $17K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $8K | +$8.15K | +1,008 | +492% |
|
|
LTFS
9
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
10
Morgan Stanley
New York
| – | -$8 | -1 | -14% |
|
SMMT Hedge Fund Activity: Q1 2016 in Review
10 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2016, worth a combined $18.3M — down 44% from $32.6M a quarter earlier.
Fund positioning in SMMT was balanced in Q1 2016: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 4 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $8.15K. The largest seller was EverPoint Asset Management, cutting an estimated $363K.
- 10 institutional investors held Summit Therapeutics (SMMT) as of Q1 2016, down from 11 in Q4 2015.
- Funds reported $18.3M of Summit Therapeutics stock for Q1 2016, down 44% quarter-over-quarter.
- 0 funds opened new Summit Therapeutics positions in Q1 2016 and 0 closed out.
- The largest Summit Therapeutics buyer in Q1 2016 was Tower Research Capital (TRC), an estimated $8.15K added.
- The largest Summit Therapeutics seller in Q1 2016 was EverPoint Asset Management, an estimated $363K sold.
Based on aggregated 13F filings for Q1 2016.